Drug Trial Radar · NCT01208207
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,015
Actual
Start
Sep 27, 2010
Primary completion
Nov 12, 2014
Study completion Nov 12, 2014
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary objectives are to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg or 60 mg compared to naproxen; and to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg compared with etoricoxib 60 mg. Additionally the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study. The primary hypothesis is that the improvement in Spinal Pain Intensity visual analog scale (VAS) as measured by the time-weighted average (TWA) change from baseline over 6 weeks of treatment in Part I for etoricoxib 90 mg or 60 mg once daily is not inferior to naproxen 1000 mg.
Conditions
- Spondylitis, Ankylosing
Interventions
Part I - etoricoxib 60 mgDrug
etoricoxib 60 mg oral tablet once daily for 6 weeks
Part I - etoricoxib 90 mgDrug
etoricoxib 90 mg oral tablet once daily for 6 weeks
Part I- naproxen 1000 mgDrug
naproxen 500 mg oral tablet twice daily for 6 weeks
Part I - Placebo to naproxen 500 mgDrug
Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
Part II- etoricoxib 60 mgDrug
etoricoxib 60 mg oral tablet once daily for 20 weeks
Part II- etoricoxib 90 mgDrug
etoricoxib 90 mg oral tablet once daily for 20 weeks
Part II- naproxen 1000 mgDrug
naproxen 500 mg oral tablet twice daily for 20 weeks
Part I - Placebo to etoricoxib 60 mgDrug
Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
Part I - Placebo to etoricoxib 90 mgDrug
Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Part II- Placebo to etoricoxib 60 mgDrug
Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Part II - Placebo to etoricoxib 90 mgDrug
Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Part II- Placebo to naproxen 500 mgDrug
Placebo to naproxen 500 mg orally twice daily for 20 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. NaproxenTime frame: Baseline and up to Week 6
- Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. NaproxenTime frame: Baseline and up to Week 6
- Number of Participants Discontinuing Study Treatment Due to an Adverse EventTime frame: Up to 26 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.